Extended interval dosing with ocrelizumab in multiple sclerosis

Background: This study investigates clinical and biomarker differences between standard interval dosing (SID) and extended interval dosing (EID) of ocrelizumab therapy in multiple sclerosis (MS). Methods: This is a prospective, double-arm, open-label, multi-center study in Denmark. Participants diag...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Multiple sclerosis 2024-06, Vol.30 (7), p.847-856
Hauptverfasser:	Novak, Frederik, Bajwa, Hamza Mahmood, Østergaard, Kamilla, Berg, Jonas Munksgaard, Madsen, Jonna Skov, Olsen, Dorte Aalund, Urbonaviciute, Inga, Illes, Zsolt, Stilund, Morten Leif, Romme Christensen, Jeppe, Bramow, Stephan, Sellebjerg, Finn, Sejbaek, Tobias
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies, Monoclonal, Humanized - administration & dosage Biomarkers Biomarkers - blood Body mass index Dosage Drug Administration Schedule Female Glial fibrillary acidic protein Humans Immunologic Factors - administration & dosage Lymphocytes B Magnetic Resonance Imaging Male Middle Aged Monoclonal antibodies Multiple sclerosis Multiple Sclerosis - drug therapy Multiple Sclerosis, Relapsing-Remitting - blood Multiple Sclerosis, Relapsing-Remitting - drug therapy Prospective Studies Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!